JBIO vs KRYS vs RCUS vs IMVT vs ARQT

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Krystal Biotech, Inc. (KRYS) offers the better valuation at 47. 0x trailing P/E (41. 5x forward), making it the more compelling value choice. Analysts rate Jade Biosciences, Inc. (JBIO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Krystal Biotech, Inc.

is actually cheaper at 41. 5x.

Over the past 5 years, Krystal Biotech, Inc.

(KRYS) delivered a total return of +394. 3%, compared to -97. 7% for Jade Biosciences, Inc. (JBIO). Over 10 years, the gap is even starker: KRYS returned +29. 2% versus JBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Krystal Biotech, Inc.

(KRYS) is the lower-risk stock at 0. 98β versus Arcus Biosciences, Inc. 's 1. 98β — meaning RCUS is approximately 102% more volatile than KRYS relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Krystal Biotech, Inc. grew EPS 128. 0% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Krystal Biotech, Inc.

(KRYS) is the more profitable company, earning 52. 6% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 52. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KRYS leads at 41. 5% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Krystal Biotech, Inc.

(KRYS) trades at 41. 5x forward P/E versus 123. 5x for Arcutis Biotherapeutics, Inc. — 82. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for JBIO: 174. 9% to $44. 20.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Krystal Biotech, Inc.

(KRYS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KRYS: +29. 2%, RCUS: +37. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: JBIO is a small-cap quality compounder stock; KRYS is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.